CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2003-12-24): Glomerular filtration rate predicts seroconversion after hepatitis B vaccination

Clinical

Glomerular filtration rate predicts seroconversion after hepatitis B vaccination

Last Updated: 2003-12-24 10:20:40 -0400 (Reuters Health)

NEW YORK (Reuters Health) - When hepatitis B vaccine is given to patients with renal failure, those with earlier-stage disease are more likely to respond with seroconversion, Canadian investigators report. They say that while the mechanism involved is unclear, it should be taken into account in the management of kidney patients.

At St. Paul's Hospital in Vancouver, British Columbia, 165 patients with chronic kidney disease who had no serologic evidence of hepatitis B infection or history of hepatitis B vaccination underwent the standard vaccination schedule recommended for patients with that condition.

Dr. Gerald DaRoza and his colleagues report in the December issue of the American Journal of Kidney Diseases that the response rates to the vaccine among the study subjects, based on their stage of kidney disease.

Disease states were categorized as stage 1 (kidney damage with normal or increased glomerular filtration rate [GFR]), stage 2 (GFR: 60-89 mL/min), stage 3 (GFR: 30-59 mL/min), stage 4, (GFR: 15-29 mL/min), or stage 5 (GFR <15 ml/min or requirement for dialysis). Patients were also analyzed according to decile of GFR (in 10-mL/min categories).

Seroconversion was defined as a hepatitis B surface antigen titer greater than 10 IU at 3 months after completion of the vaccine series. According to the authors, 82% of the patients seroconverted. "There [was] a clear stepwise statistically significant decline in seroconversion when examined in 10-mL/min decrements," the authors say.

On univariate analysis, significant predictors of seroconversion included younger age, absence of diabetes, and better kidney function. Multivariate analysis showed that patients "with the lowest level of kidney function were less likely to seroconvert than those with better kidney function, independent of other factors."

In the patients with better kidney function, seroconversion rates approached those in the general population, Dr. DaRoza and colleagues found. They add, "The ability of patients to respond at earlier phases underscores the need for...an action plan delivered by the health care team that includes early vaccination."

Am J Kidney Dis 2003;42:1184-1192.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.